By switching melanogenesis from eumelanin to pheomelanin and modulating depigmenting properties of other melanocytotoxic agents
Revisiting proven dual-acting small molecules in validated mouse and hamster models could make those studies more robustand open new options for differentiation
The majority of these follow-on patent applications and granted patents cover minor modifications in the form of delivery devices, formulations and methods of treatment
Drugs do not exist in a vacuum, and GLP-1RAs may work in theory (efficacy) and still fail in the real world over time (effectiveness)
Researchers say it remains unclear whether those effects stem directly from the medications, major weight loss, hormonal changes or broader metabolic shifts happening in the body
This enzyme, in turn, activates phosphorylase kinase, which then phosphorylates glycogen phosphorylase b (PYG b), converting it into the active form called phosphorylase a (PYG a)